A

Achilles Therapeutics PLC
NASDAQ:ACHL

Watchlist Manager
Achilles Therapeutics PLC
NASDAQ:ACHL
Watchlist
Price: 1.48 USD 0.68%
Market Cap: $60.8m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
UK
Achilles Therapeutics PLC
NASDAQ:ACHL
60.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
183.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.7B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Achilles Therapeutics PLC
Glance View

Market Cap
60.8m USD
Industry
Biotechnology

Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The firm's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

ACHL Intrinsic Value
Not Available
A
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top